Lisa Astor is the Associate Editorial Director for Targeted Oncology. Astor received her Bachelor of Arts in English Literature from New York University.
Patients With Poor-Prognosis Metastatic NSCLC Benefit From Nivolumab and Ipilimumab
Nivolumab plus ipilimumab showed clinically meaningful overall survival results at 3 years among special populations of patients with metastatic non–small cell lung cancer.
HRD Mutations Propel New Approaches in Uterine Cancer
Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.
Ibrutinib Single-handedly Impacts Immune Environment in Metastatic PDAC
According to a phase 1b study, ibrutinib can modulate immune response and lead to some promising immune effects for patients with metastatic pancreatic ductal adenocarcinoma.
Evolving Landscape for Unresectable NSCLC Is Set for Next Wave of Progress
Recent successes have been observed for patients with locally advanced, unresectable non–small cell lung cancer regarding new treatment options.
Updated HER2– Metastatic Breast Cancer Guideline Embraces Sacituzumab Govitecan
An updated guideline and panel recommends treatment with sacituzumab govitecan for patients with HR-positive/HER2-negative metastatic breast cancer who are refractory to endocrine therapy.
TLR9 Pathway Activator Leads to Signs of Immune Activity With PD-1 Inhibitor in MSS mCRC
Pixatimod and nivolumab showed benefits for patients with
microsatellite-stable metastatic colorectal cancer.
HRD Biomarker Predicts Response to Neoadjuvant Chemotherapy in TNBC
Neoadjuvant chemotherapy with carboplatin has been shown to improve the pathologic complete response rate for patients with triple negative breast cancer.
Maintenance Niraparib Shows Favorable OS in Platinum-Sensitive Recurrent Ovarian Cancer
In the NORA study, a 16% reduction in the risk of death was achieved with maintenance niraparib in patients with platinum-sensitive recurrent ovarian cancer.
CD22-Directed CAR T-cell Therapy Overcomes CD19 Relapse in LBCL With High CR Rates
In a single-institution phase 1 trial, patients with large B-cell lymphoma had high overall response rates with CD22-directed CAR T-cell therapy.
Groundbreaking ADCs Are Expanding to New Settings for More Patients With Breast Cancer
Presenters at the 2022 San Antonio Breast Cancer Symposium discussed how antibody-drug conjugates have been changing the treatment landscape for patients with breast cancer.
Adding Veliparib or Pembrolizumab to Neoadjuvant Chemoradiation Not Beneficial for Locally Advanced Rectal Cancer
NRG-GI002 helps to provide further total neoadjuvant therapy outcome data from multi-institutional national clinical trials that can benchmark and be used for future locally advanced rectal cancer outcomes, according to Thomas J. George, MD, FACP.
Despite Shortcomings, Key Learnings Gleaned From Phase 3 Trials
Several studies with data released or presented in 2022 did not meet the threshold for significance or achieve their primary end points. Although such results are disappointing, takeaways from the trials can be used by the field as a whole to improve clinical trial design and achieve greater success in the future.
The Next-Generation Promise of ADCs and SERDs in Breast Cancer
The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer.
New HER2-Low Subgroup Expands Utility of HER2-Targeted Therapies
New clinical trial data have shown that patients with IHC 1+ or IHC 2+/ISH– disease, but no ERBB2 amplification, could still benefit from HER2 targeted therapies.
Neoadjuvant IO Works Its Way Into Practice for GI Cancers
Neoadjuvant immunotherapy has begun to show benefit for the treatment of patients with rectal cancer as well as for those with colorectal cancer.
Sacituzumab Govitecan Benefit in HR+/HER2– Breast Cancer Not Determined by Trop-2 Levels
Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.
Safety of Tucatinib Triplet for HER2+ Breast Cancer Sealed in Real-World Analysis
Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.
Novel MPS1 Inhibitor Shows Early Signs of Activity in Third-line HCC
In data from a first-in-human study of a novel MPS1 inhibitor in patients with advanced solid tumors, clinical activity was observed.
Phase 1 Study Shows Signals of Response With Vaccine for HPV16+ Premalignancies
In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost
all vaccinated patients with HPV16-positive premalignancies.
Novel Agent Shows Tolerability and Response Signals in Combination With Chemotherapy in mPDAC
There was a potential antitumor signal observed with NGM120 in combination with chemotherapy, according to Andrew E. Hendifar, MD.
Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification
Tepotinib plus gefitinib led to improvements in progression-free survival and overall survival in patients with EGFR-mutant non–small cell lung cancer.
Frontline Nivolumab/Ipilimumab + Chemotherapy Benefit Extends to Histology and PD-L1 Subgroups in mNSCLC
Updated data from the phase 3 CheckMate 9LA trial showed that the combination of nivolumab, ipilimumab, and 2 cycles of
chemotherapy elicited survival benefit in patients with treatment-naïve
metastatic non–small cell lung cancer.
Sunvozertinib Shows Activity and Tolerability in EGFR Exon 20+ NSCLC
In patients with non–small cell lung cancer who harbor an EGFR exon 20 insertion mutation, sunvozertinib demonstrated promising efficacy.
Tepotinib Demonstrates Durable Benefit With High-Level MET Amplification
Tepotinib was able to provide clinically meaningful activity in patients with high MET amplification non–small cell lung cancer in the VISION study, according to Xiuning Le, MD, PhD.
Investigational Combination of OX40 and 4-1BB Antibodies Shows Early Signs of Activity in Solid Tumors
The combination of ivuxolimab and utomilumab was well tolerated in patients with advanced solid tumors, according to a phase 1 study.
ESMO 2022: New Combinations and Settings in RCC Show Mixed Results
Following the success of immunotherapy-based therapy, investigators continue to explore new approaches for patients in a rapidly evolving field to continue to move the needle toward improved outcomes for patients with kidney cancer.
Multidisciplinary Care Improves Management of TRAEs in Patients Receiving Active Cancer Treatment
Two ambulatory infusion centers, Houston Methodist Baytown Hospital (Baytown) and Houston Methodist West Hospital (West), implemented the multidisciplinary program in 2020. The study continued through October 2021.
ctDNA May Predict ICI Response in NSCLC, Pooled Analysis Results Show
Many studies’ results have suggested that the use of ctDNA for monitoring responses to treatment could be a significant tool for clinical research as well as a predictive biomarker.
Greater Understanding of the Biology of NSCLC Propels Treatment Options Forward
Prior to the 20th Annual Winter Lung Cancer Conference, Mark A. Socinski, MD, spoke with Targeted Therapies in Oncology about expectations for the upcoming meeting and major topics in non–small cell lung cancer.
Study Identifies Genes Predisposing for Breast Cancer Among Women With DCIS
Identifying a number of cancer predisposition genes could help improve upon risk assessment and counseling for ductal carcinoma in situ and contralateral breast cancer.
2 Clarke Drive Cranbury, NJ 08512